公开(公告)号：WO2010099547A1

公开(公告)日：2010-09-02

申请号：PCT/US2010/025803

申请日：2010-03-01

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  NATIONAL INSTITUTE OF INFECTIOUS DISEASE ,  TSUKUBA PRIMATE RESEARCH CENTER, NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION ,  CHENG, R., Holland ,  XING, Li ,  MIYAMURA, Tatsuo ,  YASUTOMI, Yahuhiro ,  LI, Tian-Cheng ,  TAKEDA, Naokazu

Inventor： CHENG, R., Holland ,  XING, Li ,  MIYAMURA, Tatsuo ,  YASUTOMI, Yahuhiro ,  LI, Tian-Cheng ,  TAKEDA, Naokazu

IPC: A61K39/29 ,  C12Q1/70 ,  C12Q1/68

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/57 ,  C12N2740/16134 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28134

Abstract: This invention provides a peptide / nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.

Abstract translation: 本发明提供了用于免疫保护系统的口腔/粘膜，双重模态激活的肽/核酸组合物。

公开(公告)号：WO9406913A2

公开(公告)日：1994-03-31

申请号：PCT/US9308849

申请日：1993-09-17

Applicant: US GOV HEALTH & HUMAN SERV

Inventor： TSAREV SERGEI A ,  EMERSON SUZANNE U ,  PURCELL ROBERT H

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/00 ,  A61K39/29 ,  A61K39/395 ,  A61P31/12 ,  A61P43/00 ,  C07H21/00 ,  C07K14/08 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N7/00 ,  C12N15/09 ,  C12N15/113 ,  C12N15/51 ,  C12P21/02 ,  G01N33/576 ,  C07K15/00 ,  C12N15/40

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07H21/00 ,  C12N7/00 ,  C12N15/1131 ,  C12N2310/3125 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/346 ,  C12N2710/14143 ,  C12N2770/28021 ,  C12N2770/28022 ,  C12N2770/28122 ,  C12N2770/28123 ,  Y10S977/802 ,  C12N2310/3521

Abstract: A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.

Abstract translation: 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎的感染。

公开(公告)号：WO2016019890A1

公开(公告)日：2016-02-11

申请号：PCT/CN2015/086264

申请日：2015-08-06

Applicant: MEDIGEN BIOTECHNOLOGY CORP.

Inventor： LIN, Young-Sun ,  CHENG, Jinyi ,  CHIANG, Ya-Lin ,  CHEN, Ming-Cheng ,  LAI, Kuei-Tai A. ,  YANG, Chih Ya

IPC: C07K19/00 ,  C07K14/005 ,  C07K14/02 ,  C12N15/09 ,  C07K14/08 ,  C12N7/00 ,  C12N5/10 ,  A61K39/12 ,  A61K47/48 ,  A61P31/14

CPC classification number: A61K39/292 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55572 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/40 ,  C12N7/00 ,  C12N2720/12323 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10151 ,  C12N2730/10171 ,  C12N2760/16123 ,  C12N2760/16134 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16042 ,  C12N2770/16051 ,  C12N2770/16071 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/32323 ,  C12N2770/32334 ,  C12N2770/32371 ,  Y02A50/467

Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.

Abstract translation: 本发明涉及包含这种二聚融合蛋白的二聚融合蛋白和病毒样颗粒。 这些二聚融合蛋白包含携带在两个病毒结构蛋白或其片段之间的抗原或抗原性片段，其具有或不具有接头，相对于传统的单体平台，使抗原或抗原片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 本发明还涉及编码这种二聚融合蛋白的核酸和包含这种核酸的宿主细胞。 本发明还涉及包含本发明的二聚融合蛋白和/或病毒样颗粒的药物组合物，以及使用这种组合物的预防或治疗方法。

公开(公告)号：WO2015179321A2

公开(公告)日：2015-11-26

申请号：PCT/US2015/031439

申请日：2015-05-18

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： CHENG, R. Holland ,  XING, Li ,  CHEN, Chun Chieh ,  STARK, Marie Christine

IPC: A61K39/29 ,  C12N1/20

CPC classification number: C07K14/005 ,  A61K9/5169 ,  A61K2039/5258 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28142 ,  C12N2810/40 ,  G01N2333/08

Abstract: Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

Abstract translation: 提供了在表面可变环或HEV ORF2的C末端或其一部分中含有至少一部分具有一个或多个半胱氨酸残基的戊型肝炎病毒（HEV）开放阅读框2（ORF2）的修饰衣壳蛋白。 修饰的衣壳蛋白可用于形成外露表面具有半胱氨酸官能团的戊型肝炎病毒（HEV）病毒样颗粒（VLP）。 暴露的半胱氨酸官能团可以通过它们的硫醇反应性基团进行修饰。 例如，生物活性剂，例如细胞靶向配体，可以与一个或多个半胱氨酸缀合，以靶向递送化学活化的纳米帽。

公开(公告)号：WO9612807A3

公开(公告)日：1996-05-30

申请号：PCT/US9513703

申请日：1995-10-23

Applicant: GENELABS TECH INC

Inventor： FUERST THOMAS R ,  MCATEE C PATRICK ,  YARBOUGH PATRICE O ,  ZHANG YI-FAN

IPC: G01N33/576 ,  A61K38/00 ,  A61K39/00 ,  A61K39/29 ,  A61K48/00 ,  A61P31/12 ,  C07K14/08 ,  C07K16/10 ,  C12N15/00 ,  C12N15/09 ,  C12N15/40 ,  C12P21/02 ,  C12Q1/70 ,  C12R1/91 ,  C12R1/92 ,  A61K39/12 ,  G01N33/569

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/10 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2710/14143 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12Q1/707 ,  G01N33/5767

Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.

公开(公告)号：WO1996010580A2

公开(公告)日：1996-04-11

申请号：PCT/US1995013102

申请日：1995-10-03

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  TSAREV, Sergei, A. ,  EMERSON, Suzanne, U. ,  PURCELL, Robert, H.

Inventor： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

IPC: C07K14/08

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2770/28122 ,  C12N2770/28123

Abstract: A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.

Abstract translation: 披露了一种来自巴基斯坦的丙型肝炎病毒（SAR-55），涉及到目前被称为戊型肝炎的非传染性非乙型肝炎的流行病。 本发明涉及真核表达系统中SAR-55整体结构域的表达，其命名为开放阅读框架2（ORF-2）。 表达的蛋白质能够形成HEV病毒样颗粒，其可以在诊断免疫测定中作为抗原，并作为免疫原或疫苗以防止乙型肝炎感染。

公开(公告)号：WO2017020570A1

公开(公告)日：2017-02-09

申请号：PCT/CN2016/073516

申请日：2016-02-04

Applicant: MEDIGEN BIOTECHNOLOGY CORP.

Inventor： CHENG, Jinyi ,  YANG, Chih Ya ,  CHANG, Jui Che

IPC: C07K14/005 ,  A61K39/12

CPC classification number: A61K39/12 ,  A61K38/00 ,  C07K14/005 ,  C07K2319/00 ,  C12N2720/12334 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2760/16034 ,  C12N2770/16022 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28134 ,  C12N2770/32334

Abstract: Dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins are provided. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragements thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. Nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids are also provided. Pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles and methods of prevention or treatment using such compositions are further provided.

Abstract translation: 提供二聚融合蛋白和包含这种二聚融合蛋白的病毒样颗粒。 这些二聚融合蛋白包含携带在具有或不具有接头的两种病毒结构蛋白或其残基之间的抗原或抗原性片段，其相对于传统的单体平台使抗原或抗原性片段和病毒结构蛋白之间的空间位阻最小化 或其片段。 这种新颖的设计提供了多价疫苗和增强的免疫原性。 还提供了编码这种二聚体融合蛋白的核酸和包含这种核酸的宿主细胞。 还提供了包含二聚体融合蛋白和/或病毒样颗粒的药物组合物以及使用这种组合物的预防或治疗方法。

公开(公告)号：WO2015179321A3

公开(公告)日：2016-01-14

申请号：PCT/US2015031439

申请日：2015-05-18

Applicant: UNIV CALIFORNIA

Inventor： CHENG R HOLLAND ,  XING LI ,  CHEN CHUN CHIEH ,  STARK MARIE CHRISTINE

IPC: A61K39/29 ,  A61K9/50 ,  A61P37/04 ,  C07H21/00 ,  C07K14/08

CPC classification number: C07K14/005 ,  A61K9/5169 ,  A61K2039/5258 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12N2770/28142 ,  C12N2810/40 ,  G01N2333/08

Abstract: Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

Abstract translation: 提供了在表面可变环或HEV ORF2的C末端或其一部分中含有至少一部分具有一个或多个半胱氨酸残基的戊型肝炎病毒（HEV）开放阅读框2（ORF2）的修饰衣壳蛋白。 修饰的衣壳蛋白可用于形成外露表面具有半胱氨酸官能团的戊型肝炎病毒（HEV）病毒样颗粒（VLP）。 暴露的半胱氨酸官能团可以通过它们的硫醇反应性基团进行修饰。 例如，生物活性剂，例如细胞靶向配体，可以与一个或多个半胱氨酸缀合，以靶向递送化学活化的纳米帽。

公开(公告)号：WO9610580A3

公开(公告)日：1996-05-23

申请号：PCT/US9513102

申请日：1995-10-03

Applicant: US GOV NAT INST HEALTH ,  TSAREV SERGEI A ,  EMERSON SUZANNE U ,  PURCELL ROBERT H

Inventor： TSAREV SERGEI A ,  EMERSON SUZANNE U ,  PURCELL ROBERT H

IPC: G01N33/576 ,  A61K35/76 ,  A61K39/00 ,  A61K39/29 ,  A61K39/395 ,  A61K48/00 ,  A61P31/12 ,  C07K14/08 ,  C07K16/10 ,  C12N1/19 ,  C12N5/10 ,  C12N7/00 ,  C12N15/00 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12R1/84 ,  C12R1/91 ,  C12R1/92 ,  C12N15/51 ,  C12Q1/70

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2770/28122 ,  C12N2770/28123

Abstract: A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.

公开(公告)号：WO1996012807A2

公开(公告)日：1996-05-02

申请号：PCT/US1995013703

申请日：1995-10-23

Applicant: GENELABS TECHNOLOGIES, INC.

Inventor： GENELABS TECHNOLOGIES, INC. ,  FUERST, Thomas, R. ,  McATEE, C., Patrick ,  YARBOUGH, Patrice, O. ,  ZHANG, Yi-Fan

IPC: C12N15/40

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/10 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/61 ,  C12N2710/14143 ,  C12N2770/28122 ,  C12N2770/28123 ,  C12Q1/707 ,  G01N33/5767

Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.

Abstract translation: 提供抗原，其来源于被称为戊型肝炎病毒（HEV）的肠道传播的非A /非B型病毒性肝炎病毒。 特别是由HEV ORF2的羧基末端区编码的衣壳蛋白的可溶性物质与来自感染HEV的个体的血清具有免疫反应性。 在一个实施方案中，这些抗原可以由杆状病毒表达载体产生并形成病毒样颗粒（VLP）。 抗原在诊断方法和试剂盒中用作确定HEV感染个体的诊断试剂。 抗原也可用于有效预防HEV感染的方法的疫苗组合物中。